Monitor for the actual IND submission in Q4 2026 and any FDA feedback (clinical hold or acceptance). The stock may trade on binary regulatory catalysts; the absence of new clinical data or financing details limits near-term price impact.
Price Chart
Executive Summary
XORTX announced plans to submit an IND to the FDA in Q4 2026 for its XRx-026 gout program (XORLO formulation of oxypurinol), targeting a $700M+ U.S. market opportunity. The filing outlines a regulatory path toward an NDA submission in approximately one year, contingent on successful completion of a two-part clinical trial and sufficient funding. This is a pre-clinical milestone announcement with no new clinical data, making it a forward-looking catalyst rather than a material event.
Key Facts
- Planned IND submission to FDA in Q4 2026 for XRx-026 (XORLO) gout program
- Targeting NDA submission in approximately one year after successful XRX-OXY-102 trial
- Company estimates $700M+ annual U.S. market opportunity based on prior febuxostat peak sales
- XORLO is a proprietary formulation of oxypurinol, an alternative to allopurinol and febuxostat
- No new clinical data or financial figures reported in the filing
Financial Impact
No financial data reported; company estimates $700M+ annual U.S. market opportunity for XRx-026 based on prior febuxostat peak sales
Risk Factors
- IND submission may be delayed or placed on clinical hold by FDA
- XRX-OXY-102 trial may fail or not support NDA submission
- Company requires additional capital to fund development and operations
- Market opportunity estimate based on historical febuxostat sales may not be achievable
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006109 |
| Document: f6k_091826.htm | 0001171843-26-006109 |
| Document: 0001171843-26-006109-index-headers.html | 0001171843-26-006109 |
| Document: 0001171843-26-006109-index.html | 0001171843-26-006109 |
| Document: 0001171843-26-006109.txt | 0001171843-26-006109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $0.8500 (−39.72%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $0.8500 (+63.20%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $0.8500 (−63.64%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $0.8500 (−60.65%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $0.8500 (−58.74%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $0.8500 (+63.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers